SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77592.91
826.99 (1.08%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Kovai Medical Center & Hospital Ltd.	Q V PT	6,425 Small Cap	5,880.50 (0.15%)	26.28	4.87	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Abbott India Ltd.	Q V PT	59,301 Mid Cap	27,900 (-0.03%)	38.21	12.49	9.96	17.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Glaxosmithkline Pharmaceuticals Ltd.	Q V+ PT	44,744 Mid Cap	2,655.90 (0.56%)	43.19	19.6	5.49	17.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Supriya Lifescience Ltd.	Q V+ PT	6,684 Small Cap	856 (3.07%)	31.96	5.58	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Vijaya Diagnostic Centre Ltd.	Q V PT	13,987 Small Cap	1,362.45 (0.33%)	80.86	14.61	15.00	18.43	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	CORONA Remedies Ltd.	Q V+ PT	12,654 Small Cap	2,119.85 (2.46%)	68.45	16.96	19.49	18.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Morepen Laboratories Ltd.	Q V PT	3,030 Small Cap	56.20 (1.65%)	45.86	2.44	14.44	19.03	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Anthem Biosciences Ltd.	Q V PT	44,169 Mid Cap	790.90 (0.88%)	70.76	13.58	13.62	19.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	Shree Ganesh Remedies Ltd.	Q V PT	798 Small Cap	620 (-0.23%)	44.89	4.89	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Caplin Point Laboratories Ltd.	Q V PT	19,681 Small Cap	2,606.10 (0.65%)	30.69	5.49	17.55	21.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	Syncom Formulations (India) Ltd.	Q V PT	1,216 Small Cap	13.11 (1.31%)	16	2.95	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	RPG Life Sciences Ltd.	Q V+ PT	4,765 Small Cap	2,838.65 (-1.47%)	41.37	7.87	12.70	21.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Gufic Biosciences Ltd.	Q V PT	3,881 Small Cap	383.50 (-0.92%)	61.46	5.84	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Shalby Ltd.	Q V+ PT	1,742 Small Cap	161.90 (0.37%)	15.43	1.4	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Rubicon Research Ltd.	Q V+ PT	25,392 Small Cap	1,520 (-0.91%)	134.94	18.76	32.49	25.95	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	Poly Medicure Ltd.	Q V PT	16,710 Small Cap	1,682 (2.03%)	49.73	5.47	19.91	26.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Vimta Labs Ltd.	Q V+ PT	2,694 Small Cap	599.95 (-0.46%)	33.81	5.72	14.27	28.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Indraprastha Medical Corporation Ltd.	Q V+ PT	3,376 Small Cap	362.50 (-1.56%)	18.39	4.56	10.30	29.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Apollo Hospitals Enterprise Ltd.	Q V+ PT	1,28,055 Large Cap	8,932 (0.29%)	85.79	12.85	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	Wanbury Ltd.	Q V+ PT	1,092 Small Cap	311.50 (-0.32%)	16.51	7.56	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,444 Small Cap	5,043.90 (-0.27%)	34.87	7.06	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Lupin Ltd.	Q V PT	1,09,494 Mid Cap	2,448.35 (2.24%)	20.53	4.89	13.02	32.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Natco Pharma Ltd.	Q V PT	16,561 Small Cap	939.35 (1.59%)	11.68	1.8	18.26	32.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Marksans Pharma Ltd.	Q V+ PT	11,637 Small Cap	260.25 (1.34%)	38.7	7.04	22.06	32.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Global Health Ltd.	Q V PT	37,590 Small Cap	1,405.10 (0.50%)	75.75	9.35	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Rainbow Childrens Medicare Ltd.	Q V PT	14,920 Small Cap	1,485 (1.09%)	59.67	8.85	20.26	35.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Kwality Pharmaceuticals Ltd.	Q V+ PT	2,687 Small Cap	2,575 (-0.55%)	39.89	8.08	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Neuland Laboratories Ltd.	Q V+ PT	24,197 Small Cap	19,283.10 (2.24%)	66.64	12.97	16.64	37.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	Jagsonpal Pharmaceuticals Ltd.	Q V+ PT	1,477 Small Cap	226.70 (1.21%)	34.28	6.22	11.13	39.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Jupiter Life Line Hospitals Ltd.	Q V PT	10,761 Small Cap	324.60 (-1.11%)	56.23	6.69	21.03	54.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Artemis MedicareServ	291.50	5.16%
Dr. Lal Pathlabs	1,884.15	4.31%
Concord Biotech	1,300	3.65%
Suven Life Sciences	304.30	3.42%
Sun Pharma Adv. Res	215.70	3.21%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Fischer Medical	36	-2.28%
Nectar Lifesciences	10.06	-1.66%
Indraprastha Medical	362.50	-1.56%
RPG Life Sciences	2,838.65	-1.47%
Kopran	196.50	-1.28%

News about Top Pharma Companies in India

Jul, 2026

Anthem Biosciences informs about transcript of conference call

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anthem Biosciences has informed that it enclosed the transcript of the earnings conference call held on July 22, 2026, at 11:30 AM, post announcement of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. The said transcript is also available on website of the Company at https://anthembio.com/.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Rainbow Children’s Medicare informs about ESG rating

Pursuant to Regulation 30 of the SEBI Listing Regulations read with Schedule III thereto and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Rainbow Children’s Medicare has informed that CRISIL ESG Rating & Analytics (‘CRISIL ESG’) has on a voluntary basis assessed the overall Environmental, Social and Governance (ESG) and has assigned an ESG rating of 61 and a Core ESG rating of 73, based on disclosures for FY 2025-26, on July 22, 2026. The ESG rating of 61 reflects an improvement from ‘Adequate’ to ‘Strong’ ESG rating assigned to the Company for FY 2024-25 and FY 2023-24. The Company has not engaged CRISIL ESG for ESG Ratings. CRISIL ESG has independently prepared the report based on data pertaining to FY 2025-26 for the Company available in public domain.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Rubicon Research soars on acquiring manufacturing facility in New Jersey, US

This site will focus on the company’s specialty and high value products as well as demand from US government departments

Jul, 2026

Supriya Lifescience informs about newspaper advertisement

In terms of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Supriya Lifescience has informed that it enclosed copies of the newspaper advertisement extract for Postal Ballot Notice published in the newspapers, Financial Express (English Language) and Loksatta (Marathi Language).

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Rubicon Research acquires manufacturing facility in New Jersey, US

This site will focus on the company’s specialty and high value products as well as demand from US government departments

Jul, 2026

Wanbury informs about updates

Further to its letter dated 20th July, 2026, Wanbury has informed that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company's facility at Tanuku, West Godavari District, Andra Pradesh during the period from July 13, 2026 to July 17, 2026. At the conclusion of the inspection, the USFDA has issued a Form 483 with six observations. The Company will respond to these observations to FDA within the stipulated time. The relevant disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/ 49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided in Annexure - I.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	199 Crore
2	Health X Platform Ltd.	968 Crore
3	Indoco Remedies Ltd.	2,105 Crore
4	Unichem Laboratories Ltd.	3,763 Crore
5	Solara Active Pharma Sciences Ltd.	2,446 Crore
6	Suraksha Diagnostic Ltd.	1,297 Crore
7	Jubilant Pharmova Ltd.	15,366 Crore
8	Dishman Carbogen Amcis Ltd.	2,857 Crore
9	Biocon Ltd.	70,452 Crore
10	Shilpa Medicare Ltd.	11,839 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,900	59,301	38.21	12.49	26.17	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,884	1,86,354	86.14	22.16	44.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,448	1,09,494	20.53	4.89	11.88	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,397	41,675	39.47	9.21	26.67	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,678	67,559	30.92	4.83	22.42	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,789	94,987	97.82
Sai Life Sciences Ltd. (S)	Very Good	1,316	27,605	57.56
Aurobindo Pharma Ltd. (M)	Very Good	1,582	89,212	37.52
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,884	1,86,354	35.15
Lupin Ltd. (M)	Somewhat Good	2,448	1,09,494	22.15
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,316	27,605	80.84	11.01	42.51	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,397	41,675	39.47	9.21	26.67	13.54
Mankind Pharma Ltd. (M)	Very Good	2,602	1,08,129	53.07	6.61	33.20	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,125	1,09,686	21.76	4.22	13.36	13.52
Lupin Ltd. (M)	Somewhat Good	2,448	1,09,494	20.53	4.89	11.88	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,448	1,09,494	20.53	4.89	11.88	32.37
Abbott India Ltd. (M)	Very Good	27,900	59,301	38.21	12.49	26.17	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,144	94,790	29.42	2.48	15.11	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,125	1,09,686	21.76	4.22	13.36	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,976	4,74,397	41.33	5.68	23.70	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Anthem Biosciences informs about transcript of conference call

Rainbow Children’s Medicare informs about ESG rating

Rubicon Research soars on acquiring manufacturing facility in New Jersey, US

Supriya Lifescience informs about newspaper advertisement

Rubicon Research acquires manufacturing facility in New Jersey, US

Wanbury informs about updates

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.